Article Versions Notes

Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G, Lorusso D. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers. 2021; 13(6):1298. https://doi.org/10.3390/cancers13061298

Nero, Camilla, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, and Domenica Lorusso. 2021. "Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors" Cancers 13, no. 6: 1298. https://doi.org/10.3390/cancers13061298

Nero, C., Ciccarone, F., Pietragalla, A., Duranti, S., Daniele, G., Salutari, V., Carbone, M. V., Scambia, G., & Lorusso, D. (2021). Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers, 13(6), 1298. https://doi.org/10.3390/cancers13061298